Skip to content

Characteristics of conjunctival flora in lacrimal duct diseases

Characteristics of conjunctival flora in lacrimal duct diseases

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020542
Enrollment
Unknown
Registered
2019-01-07
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lacrimal duct diseases

Interventions

Chronic dacryocystitis:Surgical treatment
Obstruction of lacrimal passage :Surgical treatment
Acute dacryocystitis:Surgical treatment
Lacrimal canaliculitis :Surgical treatment

Sponsors

Tianjin Medical University Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged at least 20 years old men and women; 2. duration: unlimited; 3. Indications: patients diagnosed as functional epiphora, lacrimal duct stenosis, lacrimal duct obstruction, chronic dacryocystitis, acute dacryocystitis; 4. Subjects have treatment needs, fully understand the condition, and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Those who did not meet the criteria for selection; (2) those who used glucocorticoid therapy within three months; (3) those who used oral or intravenous antibiotics within three months; (4) those who used antibiotic ophthalmic treatment within one week (except acute dacryocystitis); (5) those who suffered from blepharitis, blepharitis, entropion, ectropion, keratitis and other external eye and ocular diseases within three months or who had received eye surgery; (6) patients with severe skin diseases such as acne and rosacea; (7) patients with severe systemic diseases such as diabetes mellitus, autoimmune diseases, renal insufficiency and dialysis therapy; (8) medical history, personal history and allergic history that may interfere with the test results or increase the risk of patients according to the judgement of the researchers; (9) patients who have participated in other drug clinical trials in the last three months; (10) can not regularly follow-up or failure to cooperate with researchers.

Design outcomes

Primary

MeasureTime frame
Number and type of flora;

Countries

China

Contacts

Public ContactLin Tingting

Tianjin Medical University

ltt6123@126.com+86 15522858336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026